M S Saag

Summary

Affiliation: University of Alabama at Birmingham
Country: USA

Publications

  1. pmc CD4 count at presentation for HIV care in the United States and Canada: are those over 50 years more likely to have a delayed presentation?
    Keri N Althoff
    Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, 615 N Wolfe St, Baltimore, MD, 21205, USA
    AIDS Res Ther 7:45. 2010
  2. pmc When to start antiretroviral therapy: as soon as possible
    Ricardo A Franco
    Department of Medicine, Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, AL 35294, USA
    BMC Med 11:147. 2013
  3. ncbi request reprint A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis. National Institute of Allergy and Infectious Diseases Mycoses Study Group
    M S Saag
    Department of Medicine, Comprehensive Cancer Center, University of Alabama School of Medicine at Birmingham 35294 2050, USA
    Clin Infect Dis 28:291-6. 1999
  4. ncbi request reprint The experts speak. Burn-out among HIV care providers. Interview by Vicki Glaser
    Michael S Saag
    AIDS Clinic and Center for AIDS Research, University of Alabama at Birmingham, USA
    AIDS Patient Care STDS 20:385-90. 2006
  5. ncbi request reprint Once-weekly epoetin alfa improves quality of life and increases hemoglobin in anemic HIV+ patients
    Michael S Saag
    AIDS Outpatient Clinic, University of Alabama at Birmingham, Alabama 35294, USA
    AIDS Res Hum Retroviruses 20:1037-45. 2004
  6. doi request reprint A double-blind, placebo-controlled trial of maraviroc in treatment-experienced patients infected with non-R5 HIV-1
    Michael Saag
    School of Medicine, University of Alabama, Birmingham, AL 35294 2050, USA
    J Infect Dis 199:1638-47. 2009
  7. ncbi request reprint Emtricitabine, a new antiretroviral agent with activity against HIV and hepatitis B virus
    Michael S Saag
    Division of Infectious Disease, Department of Medicine, University of Alabama, Birmingham, AL 39294 2050, USA
    Clin Infect Dis 42:126-31. 2006
  8. ncbi request reprint Duration of highly active antiretroviral therapy regimens
    Ray Y Chen
    Department of Medicine, Division of Infectious Diseases, University of Alabama at Birmingham, 35294 2050, USA
    Clin Infect Dis 37:714-22. 2003
  9. ncbi request reprint Treatment of fluconazole-refractory oropharyngeal candidiasis with itraconazole oral solution in HIV-positive patients
    M S Saag
    University of Alabama at Birmingham 35294 2050, USA
    AIDS Res Hum Retroviruses 15:1413-7. 1999
  10. ncbi request reprint Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America
    M S Saag
    University of Alabama at Birmingham, 35294 2050, USA For the Mycoses Study Group Cryptococcal Subproject
    Clin Infect Dis 30:710-8. 2000

Research Grants

  1. ADULT AIDS CLINICAL TRIALS GROUP
    Michael Saag; Fiscal Year: 2004
  2. Alabama-Clinical Trials Unit
    Michael Saag; Fiscal Year: 2007
  3. UAB CENTER FOR AIDS RESEARCH
    Michael Saag; Fiscal Year: 2007
  4. RECENT ADVANCES IN AIDS AND HIV RESEARCH
    Michael Saag; Fiscal Year: 2007
  5. Unsolicited R24 for the CFAR-Network of Integrated Clinical Sciences, CNICS
    Michael Saag; Fiscal Year: 2007
  6. ADULT AIDS CLINICAL TRIALS GROUP
    Michael Saag; Fiscal Year: 2007

Collaborators

Detail Information

Publications80

  1. pmc CD4 count at presentation for HIV care in the United States and Canada: are those over 50 years more likely to have a delayed presentation?
    Keri N Althoff
    Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, 615 N Wolfe St, Baltimore, MD, 21205, USA
    AIDS Res Ther 7:45. 2010
    ..10%, respectively). Due to the increasing proportion, consistently lower CD4 counts, and more advanced HIV disease in adults ≥50-year-old at first presentation for HIV care, renewed HIV testing efforts are needed...
  2. pmc When to start antiretroviral therapy: as soon as possible
    Ricardo A Franco
    Department of Medicine, Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, AL 35294, USA
    BMC Med 11:147. 2013
    ..The pendulum has swung back and forth based mostly on the relative efficacy, toxicity and convenience of available regimens...
  3. ncbi request reprint A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis. National Institute of Allergy and Infectious Diseases Mycoses Study Group
    M S Saag
    Department of Medicine, Comprehensive Cancer Center, University of Alabama School of Medicine at Birmingham 35294 2050, USA
    Clin Infect Dis 28:291-6. 1999
    ..27-27.14; P = .04). Fluconazole remains the treatment of choice for maintenance therapy for AIDS-associated cryptococcal disease. Flucytosine may contribute to the prevention of relapse if used during the first 2 weeks of primary therapy...
  4. ncbi request reprint The experts speak. Burn-out among HIV care providers. Interview by Vicki Glaser
    Michael S Saag
    AIDS Clinic and Center for AIDS Research, University of Alabama at Birmingham, USA
    AIDS Patient Care STDS 20:385-90. 2006
  5. ncbi request reprint Once-weekly epoetin alfa improves quality of life and increases hemoglobin in anemic HIV+ patients
    Michael S Saag
    AIDS Outpatient Clinic, University of Alabama at Birmingham, Alabama 35294, USA
    AIDS Res Hum Retroviruses 20:1037-45. 2004
    ..Hemoglobin increased significantly in all subgroups of race, zidovudine use, CD4+ cell count, and viral load. Once-weekly epoetin alfa was well tolerated. Once-weekly epoetin alfa is effective in improving QOL and Hb measures...
  6. doi request reprint A double-blind, placebo-controlled trial of maraviroc in treatment-experienced patients infected with non-R5 HIV-1
    Michael Saag
    School of Medicine, University of Alabama, Birmingham, AL 35294 2050, USA
    J Infect Dis 199:1638-47. 2009
    ..A phase 2b study was conducted to determine the safety and efficacy of maraviroc in combination with optimized background therapy in treatment-experienced patients infected with dual- or mixed-tropic HIV-1...
  7. ncbi request reprint Emtricitabine, a new antiretroviral agent with activity against HIV and hepatitis B virus
    Michael S Saag
    Division of Infectious Disease, Department of Medicine, University of Alabama, Birmingham, AL 39294 2050, USA
    Clin Infect Dis 42:126-31. 2006
    ....
  8. ncbi request reprint Duration of highly active antiretroviral therapy regimens
    Ray Y Chen
    Department of Medicine, Division of Infectious Diseases, University of Alabama at Birmingham, 35294 2050, USA
    Clin Infect Dis 37:714-22. 2003
    ..6 years, and medication toxicity-associated events were the cause of one-half of discontinuations. Only a history of opportunistic infection and injection drug use were significantly associated with shorter regimen duration...
  9. ncbi request reprint Treatment of fluconazole-refractory oropharyngeal candidiasis with itraconazole oral solution in HIV-positive patients
    M S Saag
    University of Alabama at Birmingham 35294 2050, USA
    AIDS Res Hum Retroviruses 15:1413-7. 1999
    ..This trial demonstrates that itraconazole oral solution is a useful therapy in the treatment of HIV-infected patients with fluconazole-refractory oropharyngeal candidiasis...
  10. ncbi request reprint Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America
    M S Saag
    University of Alabama at Birmingham, 35294 2050, USA For the Mycoses Study Group Cryptococcal Subproject
    Clin Infect Dis 30:710-8. 2000
    ..In all cases of cryptococcal meningitis, careful attention to the management of intracranial pressure is imperative to assure optimal c..
  11. ncbi request reprint The impact of highly active antiretroviral therapy on HIV-specific immune function
    M S Saag
    AIDS Clinical Trials Unit, The University of Alabama at Birmingham, 35294 2050, USA
    AIDS 15:S4-10. 2001
    ..The long-term goal is to discontinue HAART and permit the reconstituted immune system to contain whatever small amounts of the virus remain...
  12. ncbi request reprint Phenotypic drug susceptibility testing predicts long-term virologic suppression better than treatment history in patients with human immunodeficiency virus infection
    S A Call
    Division of General Internal Medicine and Birmingham Veterans Affairs Medical Center, University of Alabama at Birmingham School of Medicine, Birmingham, AL 35294-0006, USA
    J Infect Dis 183:401-8. 2001
    ..In this cohort, phenotypic testing results enhanced the ability to predict sustained long-term suppression of virus load...
  13. ncbi request reprint Randomized, double-blind comparison of two nelfinavir doses plus nucleosides in HIV-infected patients (Agouron study 511)
    M S Saag
    University of Alabama at Birmingham, Alabama 35294-2050, USA
    AIDS 15:1971-8. 2001
    ..CONCLUSIONS: Nelfinavir plus ZDV/3TC was superior to ZDV/3TC/placebo. In addition, the 750 mg tid nelfinavir dose was better than the 500 mg tid dose. Virologic responses were sustained over 12 months...
  14. ncbi request reprint Initiation of antiretroviral therapy: implications of recent findings
    Michael S Saag
    University of Alabama at Birmingham, Birmingham, Alabama, USA
    Top HIV Med 12:83-8. 2004
    ..This article summarizes a presentation on initiation of antiretroviral therapy by Michael S. Saag, MD, at International AIDS Society-UsA course in New York in March 2004...
  15. pmc The therapeutic implications of timely linkage and early retention in HIV care
    Kimberly B Ulett
    University of Alabama School of Medicine, Birmingham, Alabama, USA
    AIDS Patient Care STDS 23:41-9. 2009
    ..Missed clinic visits represent an important obstacle to the timely initiation of antiretroviral therapy. These data inform development of interventions to improve linkage and retention in HIV care, an emerging area of growing importance...
  16. doi request reprint Antiretroviral prescribing patterns in treatment-naïve patients in the United States
    James A McKinnell
    Division of Infectious Diseases, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA
    AIDS Patient Care STDS 24:79-85. 2010
    ..In contrast, regimen sequencing beyond the first regimen remained complex. These shifts in ART prescribing patterns may have implications for collaborative HIV care...
  17. ncbi request reprint A randomized trial of 2 different 4-drug antiretroviral regimens versus a 3-drug regimen, in advanced human immunodeficiency virus disease
    Margaret A Fischl
    Department of Medicine, University of Miami School of Medicine, Miami, Florida 33101, USA
    J Infect Dis 188:625-34. 2003
    ..A 4-drug regimen containing efavirenz plus indinavir resulted in a superior virologic response, whereas one containing nelfinavir plus indinavir resulted in an inferior response and a greater likelihood of toxicity...
  18. pmc Evaluation of the single-item self-rating adherence scale for use in routine clinical care of people living with HIV
    B J Feldman
    Department of Medicine, Harborview Medical Center, University of Washington, 325 9th Ave, Box 359931, Seattle, WA 98104, USA
    AIDS Behav 17:307-18. 2013
    ..These results and the SRSI's low patient burden suggest its routine use could be helpful for assessing adherence in clinical care and should be more widespread, particularly where more complex instruments may be impractical...
  19. pmc Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy
    Xiping Wei
    Howard Hughes Medical Institute, Department of Medicine, University of Alabama at Birmingham, 35294, USA
    Antimicrob Agents Chemother 46:1896-905. 2002
    ..These findings provide the first evidence for the rapid emergence of clinical resistance to a novel class of HIV-1 entry inhibitors and may be relevant to future treatment strategies involving these agents...
  20. ncbi request reprint Efficacy and safety of emtricitabine vs stavudine in combination therapy in antiretroviral-naive patients: a randomized trial
    Michael S Saag
    University of Alabama Research Clinic, Birmingham, USA
    JAMA 292:180-9. 2004
    ..Emtricitabine is a new, once-daily nucleoside reverse transcriptase inhibitor (NRTI) with potent activity against human immunodeficiency virus (HIV)...
  21. ncbi request reprint Can routine clinical markers be used longitudinally to monitor antiretroviral therapy success in resource-limited settings?
    Shashwatee Bagchi
    Division of Geographic Medicine and Center for AIDS Research, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA
    Clin Infect Dis 44:135-8. 2007
    ..No clinically meaningful variables were identified that predicted virologic or immunological success, implying that the CD4+ cell count and HIV type 1 RNA level data are required for optimal management of antiretroviral therapy...
  22. pmc Comparative efficacy versus effectiveness of initial antiretroviral therapy in clinical trials versus routine care
    Justin S Routman
    Divisions of Infectious Diseases, Department of Medicine, University of Alabama School of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294 2050, USA
    Clin Infect Dis 50:574-84. 2010
    ..Although well-chronicled in many conditions, the efficacy versus effectiveness of antiretroviral therapy (ART) remains understudied...
  23. doi request reprint Clinical outcome of HIV-infected antiretroviral-naive patients with discordant immunologic and virologic responses to highly active antiretroviral therapy
    Ruimin Tan
    Department of Epidemiology, School of Public Health, University of Alabama at Birmingham, Birmingham, AL 35294 0022, USA
    J Acquir Immune Defic Syndr 47:553-8. 2008
    ..The prognostic significance of a response to highly active antiretroviral therapy (HAART) that is immunologically and virologically discordant is not well understood...
  24. doi request reprint Early virologic suppression with three-class experienced patients: 24-week effectiveness in the darunavir outcomes study
    James A McKinnell
    Division of Infectious Diseases, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA
    AIDS 23:1539-46. 2009
    ....
  25. ncbi request reprint Immunologic and virologic consequences of temporary antiretroviral treatment interruption in clinical practice
    Ray Y Chen
    Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama 35294, USA
    AIDS Res Hum Retroviruses 18:909-16. 2002
    ..We conclude that the majority of our patients in virologic failure who underwent a temporary TI recovered 90% of their baseline CD4(+) cell counts and returned to within 2-fold of their baseline VL when HAART was resumed...
  26. pmc Short-term discontinuation of HAART regimens more common in vulnerable patient populations
    Lindsay S Robison
    University of Alabama at Birmingham, Birmingham, Alabama 35294, USA
    AIDS Res Hum Retroviruses 24:1347-55. 2008
    ..S. HIV/AIDS epidemic. More vigilant monitoring of patient populations at higher risk of toxicity and virologic failure may allow for improved HAART regimen durability...
  27. pmc Initial increase in blood CD4(+) lymphocytes after HIV antiretroviral therapy reflects redistribution from lymphoid tissues
    R P Bucy
    Department of Pathology, University of Alabama Birmingham, Birmingham, Alabama 35233 7331, USA
    J Clin Invest 103:1391-8. 1999
    ....
  28. doi request reprint Treatment response in acute/early infection versus advanced AIDS: equivalent first and second phases of HIV RNA decline
    J Michael Kilby
    Division of Infectious Diseases and 1917 HIV Research Clinic, University of Alabama at Birmingham School of Medicine, Birmingham, Alabama 35294 2050, USA
    AIDS 22:957-62. 2008
    ..Compare the initial phases of virologic decay when acute/early and advanced HIV-infected adults are administered the same treatment regimen...
  29. doi request reprint Durability of initial antiretroviral therapy in a resource-constrained setting and the potential need for zidovudine weight-based dosing
    James H Willig
    Department of Medicine, Division of Infectious Diseases, University of Alabama at Birmingham, AL, USA
    J Acquir Immune Defic Syndr 53:215-21. 2010
    ..Whereas access to antiretroviral therapy (ART) for HIV-infected individuals in the developing world is increasing, data on factors impacting initial regimen durability are lacking...
  30. pmc Gender differences in discontinuation of antiretroviral treatment regimens
    Mirjam Colette Kempf
    Department of Epidemiology, School of Public Health, University of Alabama at Birmingham, Birmingham, AL 35294 0022, USA
    J Acquir Immune Defic Syndr 52:336-41. 2009
    ..Reported reasons for change or discontinuation of antiretroviral therapy ([delta]ART) include adverse events, intolerability, and nonadherence. Little is known how reasons for [delta]ART differ by gender...
  31. ncbi request reprint Failure to establish HIV care: characterizing the "no show" phenomenon
    Michael J Mugavero
    Division of Infectious Diseases and International Health, Department of Medicine, University of Alabama at Birmingham, USA
    Clin Infect Dis 45:127-30. 2007
    ....
  32. ncbi request reprint Nucleoside reverse-transcriptase inhibitor dosing errors in an outpatient HIV clinic in the electronic medical record era
    James H Willig
    Division of Infectious Diseases, Department of Medicine, University of Alabama at Birmingham, USA
    Clin Infect Dis 45:658-61. 2007
    ..Understanding the factors related to nucleoside reverse-transcriptase inhibitor dosing errors is an important step in the building of preventive tools...
  33. pmc Missed visits and mortality among patients establishing initial outpatient HIV treatment
    Michael J Mugavero
    Division of Infectious Diseases, Department of Medicine, University of Alabama at Birmingham, 908 20th St South, Birmingham, AL 35294 2050, USA
    Clin Infect Dis 48:248-56. 2009
    ....
  34. pmc Adherence to first-line antiretroviral therapy affects non-virologic outcomes among patients on treatment for more than 12 months in Lusaka, Zambia
    Benjamin H Chi
    Centre for Infectious Disease Research in Zambia, Lusaka, Zambia
    Int J Epidemiol 38:746-56. 2009
    ..In resource-constrained settings, however, there are few validated measures. We examined the correlation between clinical outcomes and the medication possession ratio (MPR), a pharmacy-based measure of adherence...
  35. pmc Racial disparities in HIV virologic failure: do missed visits matter?
    Michael J Mugavero
    Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, AL, USA
    J Acquir Immune Defic Syndr 50:100-8. 2009
    ..Racial/ethnic health care disparities are well described in people living with HIV/AIDS, although the processes underlying observed disparities are not well elucidated...
  36. doi request reprint Clinical inertia in the management of low-density lipoprotein abnormalities in an HIV clinic
    James H Willig
    Division of Infectious Diseases, Department of Medicine, University of Alabama at Birmingham, Birmingham, USA
    Clin Infect Dis 46:1315-8. 2008
    ..Clinical inertia was observed in 44% of cases. Patients with higher baseline LDL levels were less likely to experience inertia, whereas women and those in the highest coronary heart disease risk category were more likely to be affected...
  37. ncbi request reprint Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel
    Scott M Hammer
    Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York 10032, USA
    JAMA 296:827-43. 2006
    ..The International AIDS Society-USA panel has updated its recommendations as warranted by new developments in the field...
  38. pmc Darunavir outcomes study: comparative effectiveness of virologic suppression, regimen durability, and discontinuation reasons for three-class experienced patients at 48 weeks
    James H Willig
    Division of Infectious Diseases, Department of Internal Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA
    AIDS Res Hum Retroviruses 26:1279-85. 2010
    ..New agents have transformed the treatment landscape for ARV-experienced patients, with effectiveness in routine clinical care mirroring efficacy in clinical trials...
  39. doi request reprint Uncompensated medical provider costs associated with prior authorization for prescription medications in an HIV clinic
    James L Raper
    Department of Medicine, Division of Infectious Diseases, University of Alabama at Birmingham, AL 35294 2050, USA
    Clin Infect Dis 51:718-24. 2010
    ..60 per PA. Although evidence supports that PA reduces third-party expenditures, it significantly delays medication accessibility for patients and imposes high costs that negatively impact operating margins for health care providers...
  40. ncbi request reprint Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes
    Jeffrey S A Stringer
    Schools of Medicine and Public Health, University of Alabama at Birmingham, Birmingham, USA
    JAMA 296:782-93. 2006
    ..The Zambian Ministry of Health has scaled-up human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) care and treatment services at primary care clinics in Lusaka, using predominately nonphysician clinicians...
  41. ncbi request reprint Sustained HIV viral suppression following treatment interruption: an observational study
    Roger Bedimo
    University of Alabama, Birmingham, Alabama 85294, USA
    AIDS Res Hum Retroviruses 22:40-4. 2006
    ..Examining the immune responses of nonrebounders may contribute to the understanding of protective immunity to HIV...
  42. ncbi request reprint The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults
    J Michael Kilby
    UAB HIV Outpatient Clinic, University of Alabama at Birmingham, CCB 245A, 908 20th Street South, Birmingham, AL 35294 2050, USA
    AIDS Res Hum Retroviruses 18:685-93. 2002
    ..Injection site reactions were common but generally mild. These results indicate that enfuvirtide is a promising new therapeutic agent for HIV-infected patients, including those with prior antiretroviral treatment...
  43. pmc Increased regimen durability in the era of once-daily fixed-dose combination antiretroviral therapy
    James H Willig
    Division of Infectious Diseases, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA
    AIDS 22:1951-60. 2008
    ..Modern regimens are thought to possess greater tolerability and convenience. We hypothesized this would translate into greater durability...
  44. ncbi request reprint Sexually transmitted disease/HIV transmission risk behaviors and sexually transmitted disease prevalence among HIV-positive men receiving continuing care
    Laura H Bachmann
    Department of Medicine, The University of Alabama at Birmingham, Department of Medicine, Birmingham, Alabama, USA
    Sex Transm Dis 32:20-6. 2005
    ..Determination of the prevalence and factors associated with risk-taking behaviors among HIV clinic attendees is needed...
  45. doi request reprint Gastrointestinal complications of HIV infection: changing priorities in the HAART era
    C M Wilcox
    Department of Medicine, Division of Gastroenterology and Hepatology, Center for AIDS Research, University of Alabama at Birmingham, Birmingham, AL 35294 0007, USA
    Gut 57:861-70. 2008
    ....
  46. ncbi request reprint Enfuvirtide
    Ray Y Chen
    Department of Medicine, Division of Infectious Diseases, University of Alabama at Birmingham, 908 20th Street South, CCB 142, Birmingham, Alabama 35294 2050, USA
    Expert Opin Investig Drugs 11:1837-43. 2002
    ..Based on these studies, enfuvirtide will likely play a significant role in the treatment of patients with limited treatment options...
  47. pmc Cohort profile: the Centers for AIDS Research Network of Integrated Clinical Systems
    Mari M Kitahata
    Department of Medicine, University of Washington, Seattle, 98195, USA
    Int J Epidemiol 37:948-55. 2008
  48. pmc Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection
    Brandon F Keele
    Departments of Medicine and Microbiology, University of Alabama at Birmingham, Birmingham, AL 35223, USA
    Proc Natl Acad Sci U S A 105:7552-7. 2008
    ....
  49. doi request reprint Novel drug classes: entry inhibitors [enfuvirtide, chemokine (C-C motif) receptor 5 antagonists]
    James A McKinnell
    Department of Medicine, Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, Alabama 35294 0006, USA
    Curr Opin HIV AIDS 4:513-7. 2009
    ..To provide an update on viral entry inhibitors focusing on recently published clinical trials, the routine clinical use of these medications, and future drug candidates...
  50. ncbi request reprint Trends in AIDS-defining and non-AIDS-defining malignancies among HIV-infected patients: 1989-2002
    Roger Bedimo
    University of Alabama at Birmingham, USA
    Clin Infect Dis 39:1380-4. 2004
    ..87; P<.0002). The mean CD4 cell count was lower among patients with ADMs than among those with non-ADMs. A longer duration of survival during highly active antiretroviral therapy might explain the increasing incidence of non-ADMs...
  51. ncbi request reprint Symptomatic lactic acidosis in hospitalized antiretroviral-treated patients with human immunodeficiency virus infection: a report of 12 cases
    M E Coghlan
    Department of Medicine, University of Alabama at Birmingham School of Medicine, Birmingham, AL 35294-0006, USA
    Clin Infect Dis 33:1914-21. 2001
    ..The increasing number of cases identified during the study period suggests that physicians better recognize symptomatic lactic acidosis and/or that cumulative NRTI exposure may increase the risk for this syndrome...
  52. ncbi request reprint Decrease of cytomegalovirus replication in human immunodeficiency virus infected-patients after treatment with highly active antiretroviral therapy
    C E O'Sullivan
    Division of Infectious Diseases, Department of Medicine, University of Alabama at Birmingham School of Medicine, Birmingham AL 39294 0006, USA
    J Infect Dis 180:847-9. 1999
    ..1 to 1.7 at 385 days with a commensurate rise in median CD4 T cells to 166/mm3. Immune reconstitution secondary to HAART results in a significant and progressive decline in CMV viremia in the absence of specific anti-CMV therapy...
  53. ncbi request reprint Antibody neutralization and escape by HIV-1
    Xiping Wei
    Howard Hughes Medical Institute, University of Alabama at Birmingham, 720 South 20th Street, Kaul 816, Birmingham, Alabama 35294 0024, USA
    Nature 422:307-12. 2003
    ..The evolving glycan shield thus represents a new mechanism contributing to HIV-1 persistence in the face of an evolving antibody repertoire...
  54. ncbi request reprint Antiretroviral therapy: select lessons from recent studies
    Michael S Saag
    The University of Alabama at Birmingham, Birmingham, AL, USA
    Top HIV Med 11:164-8. 2003
  55. pmc Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection
    Jesus F Salazar-Gonzalez
    University of Alabama at Birmingham, Birmingham, AL 35294, USA
    J Exp Med 206:1273-89. 2009
    ..These findings reveal viral properties associated with mucosal HIV-1 transmission and a limited set of rapidly evolving adaptive mutations driven primarily, but not exclusively, by early cytotoxic T cell responses...
  56. ncbi request reprint Complete blood cell count as a surrogate CD4 cell marker for HIV monitoring in resource-limited settings
    Ray Y Chen
    Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA
    J Acquir Immune Defic Syndr 44:525-30. 2007
    ..We developed a more effective method based on a decision tree algorithm to classify subjects...
  57. ncbi request reprint Distribution of health care expenditures for HIV-infected patients
    Ray Y Chen
    Department of Internal Medicine, School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA
    Clin Infect Dis 42:1003-10. 2006
    ..Health care expenditures for persons infected with human immunodeficiency virus (HIV) in the United State determined on the basis of actual health care use have not been reported in the era of highly active antiretroviral therapy...
  58. pmc Hit-and-run stimulation: a novel concept to reactivate latent HIV-1 infection without cytokine gene induction
    Frank Wolschendorf
    Department of Medicine, The University of Alabama at Birmingham, Birmingham, Alabama 35294, USA
    J Virol 84:8712-20. 2010
    ..In the absence of such a positive feedback mechanism, cellular gene expression was not sustained, suggesting that strategies modulating the NF-kappaB activity profile could be used to selectively trigger HIV-1 reactivation...
  59. ncbi request reprint Patient-perceived barriers to antiretroviral adherence: associations with race
    T F Ferguson
    Department of Epidemiology, School of Public Health, University of Alabama at Birmingham UAB, 11th Avenue South, Medical Towers Suite 401, Birmingham, AL 35205 4410, USA
    AIDS Care 14:607-17. 2002
    ..Our findings support the use of theory-based behavioural interventions that address perceived barriers to adherence and other health promotion activities...
  60. pmc Measuring depression levels in HIV-infected patients as part of routine clinical care using the nine-item Patient Health Questionnaire (PHQ-9)
    P K Crane
    Department of Medicine, Harborview Medical Center, University of Washington, Seattle, WA, USA
    AIDS Care 22:874-85. 2010
    ....
  61. pmc Antigenic conservation and immunogenicity of the HIV coreceptor binding site
    Julie M Decker
    Howard Hughes Institute, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA
    J Exp Med 201:1407-19. 2005
    ..Despite remarkable evolutionary diversity among primate lentiviruses, functional constraints on receptor binding create opportunities for broad humoral immune recognition, which in turn serves to constrain the viral quasispecies...
  62. ncbi request reprint Ryan White CARE Act reauthorization: we need help
    Michael S Saag
    Center for AIDS Research, The University of Alabama at Birmingham, Birmingham, AL, USA
    Top HIV Med 14:93-4. 2006
  63. ncbi request reprint HIV protease inhibitor ritonavir induces lipoatrophy in male mice
    Eric S Goetzman
    Department of Genetics, University of Alabama at Birmingham, Alabama 35294, USA
    AIDS Res Hum Retroviruses 19:1141-50. 2003
    ..Thus, the effects of ritonavir on serum triglycerides and body composition may be due, at least in part, to an inhibition of PPAR function...
  64. ncbi request reprint Unusual thromboses associated with protein S deficiency in patients with acquired immunodeficiency syndrome: case reports and review of the literature
    Melissa S Dillmon
    Department of Medicine, University of Alabama School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama 35249, USA
    AIDS Res Hum Retroviruses 21:753-6. 2005
    ..We propose that awareness of the increased risk for thrombosis in HIV infection is important to the understanding of disease pathophysiology and management of these patients...
  65. pmc Baseline renal insufficiency and risk of death among HIV-infected adults on antiretroviral therapy in Lusaka, Zambia
    Lloyd B Mulenga
    Centre for Infectious Disease Research, Zambia
    AIDS 22:1821-7. 2008
    ..To examine the association between baseline renal insufficiency and mortality among adults initiating antiretroviral therapy (ART) in an urban African setting...
  66. ncbi request reprint Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel
    Patrick G Yeni
    Hopital Bichat Claude Bernard, Department of Infectious Diseases, 46 rue Henri Huchard, Paris, Cedex 18 France 75877
    JAMA 288:222-35. 2002
    ..These updated recommendations are intended to guide practicing physicians actively involved in human immunodeficiency virus (HIV)- and acquired immunodeficiency syndrome (AIDS)-related care...
  67. ncbi request reprint Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel
    Patrick G Yeni
    Department of Infectious Diseases, Hopital Bichat Claude Bernard, X Bichat Medical School, Paris, France
    JAMA 292:251-65. 2004
    ..Substantial changes in the field of human immunodeficiency virus (HIV) treatment have occurred in the last 2 years, prompting revision of the guidelines for antiretroviral management of adults with established HIV infection...
  68. ncbi request reprint Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1
    Gerd Fatkenheuer
    Department of Internal Medicine, Division of Infectious Diseases, Haus 11, University of Cologne, Joseph Stelzmann Strasse 9, D 50924 Cologne, Germany
    Nat Med 11:1170-2. 2005
    ..6 log(10) copies/ml at all twice daily doses >or=100 mg. These results provide proof of concept that CCR5 antagonism is a viable antiretroviral therapeutic approach...
  69. ncbi request reprint Roundtable. Who should be providing HIV care?
    Jonathan S Appelbaum
    AIDS Clin Care 18:21-4. 2006
  70. ncbi request reprint Evidence that intermittent structured treatment interruption, but not immunization with ALVAC-HIV vCP1452, promotes host control of HIV replication: the results of AIDS Clinical Trials Group 5068
    Jeffrey M Jacobson
    Beth Israel Medical Center and Albert Einstein College of Medicine, New York, NY 10003, USA
    J Infect Dis 194:623-32. 2006
    ....
  71. ncbi request reprint Which policy to ADAP-T: waiting lists or waiting lines?
    Michael S Saag
    Clin Infect Dis 43:1365-7. 2006
  72. ncbi request reprint A plea for justice for jailed medical workers
    Sunil K Ahuja
    Science 314:924-5. 2006
  73. ncbi request reprint Opt-out testing: who can afford to take care of patients with newly diagnosed HIV infection?
    Michael S Saag
    Clin Infect Dis 45:S261-5. 2007
    ....
  74. pmc Efficacy, safety and pharmacokinetics of once-daily saquinavir soft-gelatin capsule/ritonavir in antiretroviral-naive, HIV-infected patients
    Julio S G Montaner
    St Paul s Hospital, University of British Columbia, Vancouver, BC, Canada
    MedGenMed 8:36. 2006
    ..Once-daily HIV treatment regimens are being used in clinical practice with the objective of improving patient acceptance and adherence...
  75. doi request reprint Safety, tolerability, pharmacokinetics, and efficacy of an interleukin-2 agonist among HIV-infected patients receiving highly active antiretroviral therapy
    Richard T Davey
    National Institutes of Health, National Institute of Allergy and Infectious Disease, Bethesda, MD 20892, USA
    J Interferon Cytokine Res 28:89-100. 2008
    ..Bay 50-4798 was generally well tolerated across the dose range tested, but a lack of potent, sustained immunologic activity suggests that further optimization of dose and schedule will be necessary...
  76. pmc Simple adherence assessments to predict virologic failure among HIV-infected adults with discordant immunologic and clinical responses to antiretroviral therapy
    Jason D Goldman
    Centre for Infectious Disease Research in Zambia, Lusaka, Zambia
    AIDS Res Hum Retroviruses 24:1031-5. 2008
    ..Among patients with suspected treatment failure, a lower MPR was associated with higher rates of detectable viremia. However, the suboptimal sensitivity and specificity of MPR limit its utility as a sole predictor of virologic failure...
  77. ncbi request reprint Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel
    Morris Schambelan
    University of California San Francisco, San Francisco General Hospital, San Francisco, California, USA
    J Acquir Immune Defic Syndr 31:257-75. 2002
    ..These recommendations were developed to guide physicians actively involved in HIV care in the management of metabolic complications that occur primarily within the context of potent antiretroviral therapy...
  78. pmc Cohort profile: the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD)
    Stephen J Gange
    NA ACCORD Coordinating Center, Baltimore, MD 21287, USA
    Int J Epidemiol 36:294-301. 2007
  79. pmc HIV care at a crossroads: the emerging crisis in the US HIV epidemic
    Michael J Mugavero
    MedGenMed 9:58. 2007
  80. pmc Determinants of human immunodeficiency virus type 1 escape from the primary CD8+ cytotoxic T lymphocyte response
    Nicola A Jones
    Viral Immunology Group, The Edward Jenner Institute for Vaccine Research, Compton, Newbury, Berkshire RG20 7NN, England, UK
    J Exp Med 200:1243-56. 2004
    ....

Research Grants7

  1. ADULT AIDS CLINICAL TRIALS GROUP
    Michael Saag; Fiscal Year: 2004
    ....
  2. Alabama-Clinical Trials Unit
    Michael Saag; Fiscal Year: 2007
    ..administrative component: ..
  3. UAB CENTER FOR AIDS RESEARCH
    Michael Saag; Fiscal Year: 2007
    ..All of the major research efforts within the Center link basic and clinical/behavioral research, and together they utilize every shared facility supported by the CFAR Core grant. ..
  4. RECENT ADVANCES IN AIDS AND HIV RESEARCH
    Michael Saag; Fiscal Year: 2007
    ..CME credit for attending physicians will be provided. ..
  5. Unsolicited R24 for the CFAR-Network of Integrated Clinical Sciences, CNICS
    Michael Saag; Fiscal Year: 2007
    ....
  6. ADULT AIDS CLINICAL TRIALS GROUP
    Michael Saag; Fiscal Year: 2007
    ..abstract_text> ..